AIP
IONS icon

Arrowpoint Investment Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Arrowpoint Investment Partners’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.93M Buy
38,988
+13,971
+56% +$1.1M 2.6% 7
2025
Q4 		$1.98M Buy
25,017
+19,554
+358% +$1.47M 0.29% 29
2025
Q3 		$357K Buy
+5,463
New +$267K 0.36% 57

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowpoint Investment Partners's IONS Position: Q1 2026 in Review

Arrowpoint Investment Partners increased its Ionis Pharmaceuticals (IONS) stake by 56% in Q1 2026, buying an estimated $1.1M and bringing the position to 38,988 shares worth $2.93M. The position accounts for 2.6% of the portfolio, ranked #7.

Arrowpoint Investment Partners first reported a position in IONS in Q3 2025 and has held it in 3 quarters since. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Arrowpoint Investment Partners held 38,988 shares of Ionis Pharmaceuticals worth $2.93M as of Q1 2026.
  • Arrowpoint Investment Partners bought 13,971 Ionis Pharmaceuticals shares in Q1 2026, an estimated $1.1M.
  • Ionis Pharmaceuticals made up 2.6% of Arrowpoint Investment Partners's portfolio in Q1 2026, its #7 holding.
  • Arrowpoint Investment Partners first reported a position in Ionis Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q1 2026, filed 14 May 2026.